

Miyako Satouchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7474787/publications.pdf>

Version: 2024-02-01

24
papers

5,400
citations

687220

13
h-index

580701

25
g-index

25
all docs

25
docs citations

25
times ranked

5513
citing authors

#	ARTICLE	IF	CITATIONS
1	Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer. <i>Lung Cancer</i> , 2021, 159, 162-170.	0.9	6
2	First-line pembrolizumab vs chemotherapy in metastatic non-small cell lung cancer: KEYNOTE-024 Japan subset*. <i>Cancer Science</i> , 2021, 112, 5000-5010.	1.7	6
3	Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. <i>Lung Cancer</i> , 2020, 139, 195-199.	0.9	100
4	Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥ 75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORIG1323. <i>Translational Lung Cancer Research</i> , 2020, 9, 459-470.	1.3	5
5	The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients. <i>Respiratory Investigation</i> , 2020, 58, 269-274.	0.9	5
6	A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer. <i>BMC Cancer</i> , 2020, 20, 115.	1.1	6
7	Osimertinib for Japanese patients with T790M-positive advanced non-small cell lung cancer: A pooled subgroup analysis. <i>Cancer Science</i> , 2019, 110, 2884-2893.	1.7	22
8	The safety and efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel in the treatment of non-small cell lung cancer patients with interstitial lung disease. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 89-93.	0.6	27
9	Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations. <i>Lung Cancer</i> , 2018, 124, 65-70.	0.9	13
10	Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 105, 23-30.	0.9	30
11	Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. <i>Lancet</i> , 2017, 390, 29-39.	6.3	753
12	Pemetrexed monotherapy for chemo-naïve elderly (aged ≥ 80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and Tj ETQq0 0 OtrgBT /Overlock 10 TF		
13	Detection of epidermal growth factor receptor gene T790M mutation in cytology samples using the cobas EGFR mutation test. <i>Lung Cancer</i> , 2017, 111, 190-194.	0.9	13
14	Concurrent chemoradiotherapy with cisplatin and S-1 or vinorelbine for patients with stage III unresectable non-small cell lung cancer: A retrospective study. <i>Respiratory Investigation</i> , 2016, 54, 334-340.	0.9	4
15	A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109). <i>Lung Cancer</i> , 2015, 87, 136-140.	0.9	16
16	A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110). <i>Lung Cancer</i> , 2015, 89, 146-153.	0.9	16
17	A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001). <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 17-23.	1.1	2
18	Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naïve patients with advanced nonsquamous non-small cell lung cancer. <i>Cancer</i> , 2013, 119, 2275-2281.	2.0	9

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2013, 81, 97-101.	0.9	42
20	A Phase II Study of Pemetrexed in Chemotherapy-naive Elderly Patients Aged ≥ 75 years with Advanced Non-squamous Non-small-cell Lung Cancer (HANSHIN Oncology Group 003). <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 1184-1189.	0.6	10
21	Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR).. <i>Journal of Clinical Oncology</i> , 2012, 30, 7521-7521.	0.8	71
22	Phase III Study Comparing Second- and Third-Generation Regimens With Concurrent Thoracic Radiotherapy in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer: West Japan Thoracic Oncology Group WJTOG0105. <i>Journal of Clinical Oncology</i> , 2010, 28, 3739-3745.	0.8	261
23	Phase III Trial Comparing Oral S-1 Plus Carboplatin With Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients With Advanced Non-Small-Cell Lung Cancer: Results of a West Japan Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 5240-5246.	0.8	161
24	Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2010, 11, 121-128.	5.1	3,794